Letairis belongs to a group of medicines known as endothelin receptor antagonists. Endothelins are a type of protein that can cause blood vessels to constrict (narrow). People who have PAH have high levels of endothelins. Letairis works by binding to certain receptors in the body, blocking the action of the extra endothelins. As a result, the blood vessels relax and blood flow improves. Using Letairis can help slow down the progression of PAH and improve a person's ability to exercise.
Clinical studies on this drug showed that people who took Letairis were able to walk farther over a six-minute period than people who did not take the drug. It was also shown to slow down the worsening of the disease.
(Click Letairis Uses for more details on using this medicine for treating pulmonary arterial hypertension. This Web page also covers possible off-label uses and whether the drug can be used in children.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Letairis [package insert]. Foster City, CA: Gilead Sciences, Inc.;2012 October.
Ambrisentan. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2013. Available from Wolters Kluwer Health, Inc. Accessed May 31, 2013.
Letairis Web site. Available at: http://www.Letairis.com/. Accessed June 3, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click